Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Resources
Find out who is at risk for Meningococcal B disease
Meningococcal B disease is uncommon but potentially life-threatening disease that may be prevented through vaccination.1
Quick links
If you can prevent shingles suffering, why wouldn't you?3
Vaccinate now for protection that last3
More Information
Fictional patients, for illustrative purpose only.
4CMenB, Meningococcal group B Vaccine (rDNA, component, adsorbed);
Men B, Meningococcal group B; COPD, chronic obstructive pulmonary disease; FF, Fluticasone furoate; UMEC, umeclidinium; VI, vilanterol.
References:
- Pelton SI. Meningococcal disease awareness: clinical and epidemiology factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15.
- FF/UMEC/VI (Trelegy Ellipta) Prescribing Information version number : GDS06/IPI06.1 Revision date: 08 June 2021
- Recombinant Zoster Vaccine (Shingrix) Prescribing Information GDS07/IPI02 / Date of issue: 14 June 2022
- Thompson MJ; Clinical recognition of meningococcal disease in children and adolescents.Lancet;2006;367;397-403
- 4CMen B, Meningococcal group B Vaccine (rDNA, component, adsorbed) (Bexsero) Prescribing Information GDS18/IPI03/Date of issue: 30 July 2024.
- World Health Organization. Meningococcal meningitis. 17 April 2023.
GSK is not responsible for the third-party links
Trade marks are owned by or licensed to GSK group of companies.
To report adverse events please email us: ph.safety@gsk.com,
Product Complaint email us: PHLOC_Complaints@gsk.com or contact 0917 889 7050 (Quality Assurance Team)
